PRECISESADS General Assembly
The next PRECISESADS project meeting will take place on the 8th – 9th of March, 2018 in Ascot, UK. AGENDA you can register for this event at https://www.surveymonkey.com/r/RWDBLRS
Esta web utiliza cookies propias y de terceros para mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí.
Inflammatory autoimmune diseases such as rheumatoid arthritis and lupus affect 1-3% of the population, and while treatments exist, these are costly and have a number of serious side effects. There is growing evidence that many of these conditions may be incorrectly classified. The PRECISESADS project will study 2 500 people with various autoimmune diseases, gathering data on the molecular causes of their disease as well as their clinical symptoms. Using this information, they will pave the way for a new classification of these diseases, something that will allow doctors to offer patients more personalised treatments at an earlier stage of their disease.
The next PRECISESADS project meeting will take place on the 8th – 9th of March, 2018 in Ascot, UK. AGENDA you can register for this event at https://www.surveymonkey.com/r/RWDBLRS
“We are delighted to report that we have over-achieved our recruitment targets for this project. Patient recruitment can be especially difficult as patients are widely dispersed and may face issues, such as physical limitations, that can affect their ability to readily participate” says Prof Alarcón Riquelme. ‘Patients have been highly motivated and generously willing to
IV European Conference: “Genomics of Complex Diseases: New Challenges” Granada, Spain, October 4-5, 2018 Welcome The PRECISESADS Project…
The next PRECISESADS project meeting will take place on the 8th – 9th of March, 2018 in Ascot, UK. (AGENDA)…
"Novel Therapies in Autoimmune Diseases" LACA 2017, the 5th Latin American Congress on Autoimmunity will be held in the serene…
General information, list of patients associations, …
This website reflects only the author’s views and neither IMI nor the European Commission are liable for any use that may be made of the information contained therein.
PRECISESADS receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° [115565], resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases